Drug firm Vivimed Labs today said the US health regulator has completed the inspection of its manufacturing facility in Alathur.
The company's 'Finished Dosage Form' manufacturing facility has had a favourable outcome post its US Food and Drug Administration (USFDA) inspection, Vivimed Labs said in a filing to BSE.
The audit was conducted during the last week of November and concluded on November 28, 2016, it added.
Commenting on the development, Vivimed Labs MD Santosh Varalwar said: "Over the two years we have received satisfactory outcomes of USFDA inspections for our two plants in Spain, one in Mexico and one in India."
For the India plant, this was the second inspection, he added.
"We believe that this satisfactory outcome will support our endeavour to further strengthen our positioning in the global markets," Varalwar said.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)